Belimumab: First targeted biological treatment for systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Sandra Navarra, Renato Guzmán, A Gallacher et al. · The Lancet · 2011 · 2K citations

Medicine, Immunology, Pharmacology +11

Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations

Fabienne Mackay, Stephen A. Woodcock, Pornsri Lawton et al. · The Journal of Experimental Medicine · 1999 · 1.5K citations · Full text

Life Sciences, Immunology, Pathology +17

Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

Joan T. Merrill, C. Michael Neuwelt, Daniel J. Wallace et al. · Arthritis & Rheumatism · 2009 · 1.4K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +13

BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth

Pascal Schneider, Fabienne Mackay, Véronique Steiner et al. · The Journal of Experimental Medicine · 1999 · 1.3K citations · Full text

Life Sciences, Immunology, Molecular Biology +17

BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator

Paul A. Moore, Ornella Belvedere, A. S. ORR et al. · Science · 1999 · 1.1K citations

Life Sciences, Cell Biology, Immunology +13